CD8A and neoplasm: There may be additional anti-tumour benefit to also inhibiting STUB1 in immune cells, e.g., CD8+ T cell60, as well as the most relevant human cancer types, such as prostate and breast cancer, as implicated by the analysis of the TCGA dataset.